HALEOSLABS · Haleos Labs Ltd · Biotechnology & Drugs
HALEOSLABS · Haleos Labs Ltd · Biotechnology & Drugs
As of 05 Nov close
52-week range
20.5% below 52-week high
52-week range: as of 05 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 52 days old
Revenue (latest Q)
₹73 Cr
Revenue YoY
PAT YoY
-36.3%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
2.1
P/S (TTM)
1.4
Sector P/E
36.3
Dividend yield
+0.1%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| HALEOSLABS (this stock) | 27.9 | 2.1 | +4.9% | +7.4% | 0.52 | +0.1% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
stable
FII
stable
MF
Not available from data source
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
No bulk/block deals in the last 12 months.
News timeline
No related news.
Concalls & investor presentations
AI-generatedNo concall transcripts or investor presentations recorded yet.
AI Summary of Annual Report
AI-generatedHaleos Labs Limited reported a 9.72% decline in standalone revenue for FY2025-26 compared to the previous year, primarily due to customer-specific issues, process-related challenges at customer facilities, and increased raw material costs from the Middle East crisis. The company's subsidiary, Mahi Drugs, showed significant growth with a 40% increase in total income and a turnaround in profitability. Management emphasized future strategies focusing on product portfolio expansion, R&D investment, and strengthening presence in regulated global markets. The company also highlighted successful regulatory inspections in the US and Brazil, affirming its commitment to quality standards.
- The company experienced revenue decline due to customer-specific and industry-related factors, not structural issues.
- Mahi Drugs, the subsidiary, achieved significant growth in income and profitability.
- Future strategies include expanding product portfolios, enhancing R&D, and strengthening global market presence.
- Successful regulatory inspections in the US and Brazil reaffirm quality standards compliance.
Key takeaway: Haleos Labs Limited's revenue decline was attributed to external factors such as customer issues and raw material price volatility, while the company remains focused on strategic growth through product innovation and global market expansion.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Auditor Qualification (1 item); Regulatory Action (1 item)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Auditor Qualification
1 occurrenceOlder (3+ years ago)
The listed entity has not complied with SEBI Circular CIR/CFD/CMD1/114/2019 regarding auditor resignation procedures, as indicated by the 'NA' compliance status and lack of details in the report.
Regulatory Action
1 occurrenceEarlier (1-3 years ago)
The company's PAN was frozen by the depository on 01.04.2024, and temporarily unfrozen for technical facilitation to credit purchased shares to Mr. Praveen's Demat Account during the trading window closure period.
Routine disclosures
Contingent Liability
3 occurrencesRecent (last 12 months)
The company has disclosed the impact of pending litigations on its financial position in its standalone financial statements, as noted in Note 45 on contingent liabilities.
Earlier (1-3 years ago)
The company has contingent liabilities including disputed Income Tax Demands, disputed Customs duty, disputed IGST on Imports, and Non Agricultural land Tax as of 31st March, 2025.
Older (3+ years ago)
The company has disclosed the impact of pending litigations on its financial position in its standalone financial statements, as noted in Note 47 on contingent liabilities.
Related-Party Transaction
2 occurrencesRecent (last 12 months)
The company approved material related party transactions involving a corporate guarantee in favor of RBL Bank to secure external corporate borrowings by its subsidiary Mahi Drugs Private Limited.
Older (3+ years ago)
The company is seeking approval for material related party transactions for the year 2023-24.
Statutory dues in dispute
1 occurrenceRecent (last 12 months)
The company has statutory dues pending under the AP Non Agricultural Land (Conversion for Non Agriculture Purpose) Act, 2006 and the Employees Provident Fund and Miscellaneous Provisions Act, 1952, with disputes pending in the High Court of Telangana and NCLT Hyderabad respectively.
Management & Board Governance
1 occurrenceRecent (last 12 months)
The National Stock Exchange of India (NSE) sent a Cautionary Letter to the company regarding unfreezing the PAN of a designated person during the trading window closure period, advising caution to avoid recurrence and ensure compliance with SEBI regulations.
Promoter Share Pledge
1 occurrenceRecent (last 12 months)
1.1% of promoter holding pledged (quarter 2026-Q3 as of 2026-07-18).